Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1997 1
2002 1
2008 1
2009 1
2010 1
2011 1
2015 1
2016 1
2019 1
2020 2
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20CJ, 5BAuthor
Page 1
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.
Becker F, Dakin HA, Reed SD, Li Y, Leal J, Gustavson SM, Wittbrodt E, Hernandez AF, Gray AM, Holman RR. Becker F, et al. Diabetes Res Clin Pract. 2022 Jan;183:109152. doi: 10.1016/j.diabres.2021.109152. Epub 2021 Nov 20. Diabetes Res Clin Pract. 2022. PMID: 34813910 Free PMC article.
We assessed the lifetime cost-effectiveness of adding EQW vs. usual care alone from a healthcare perspective. METHODS: Medical resource use and EQ-5D utilities were collected throughout the study. Within-trial results were extrapolated to a lifetime horizon using the UK Pr …
We assessed the lifetime cost-effectiveness of adding EQW vs. usual care alone from a healthcare perspective. METHODS: Medical resource use …
Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial.
Leal J, Becker F, Lim LL, Holman RR, Gray AM. Leal J, et al. J Diabetes. 2022 Jul;14(7):455-464. doi: 10.1111/1753-0407.13294. J Diabetes. 2022. PMID: 35876124 Free PMC article. Clinical Trial.
METHODS: Health-related quality of life was captured using the EuroQol-5 Dimension-3 Level (EQ-5D-3L), with data collected at baseline and throughout the trial. ...RESULTS: Patients were followed for a median of 5 years (interquartile range 3.4-6.0). The average baseline E …
METHODS: Health-related quality of life was captured using the EuroQol-5 Dimension-3 Level (EQ-5D-3L), with data collected at baselin …
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Reed SD, Li Y, Dakin HA, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, Pagidipati NJ, Bethel MA, Gray AM, Holman RR, Hernandez AF; EXSCEL Study Group. Reed SD, et al. Diabetes Care. 2020 Feb;43(2):374-381. doi: 10.2337/dc19-0950. Epub 2019 Dec 5. Diabetes Care. 2020. PMID: 31806653 Free PMC article. Clinical Trial.
RESEARCH DESIGN AND METHODS: Medical resource use data and responses to the EuroQol 5-Dimension (EQ-5D) instrument were collected at baseline and throughout the trial. ...With English costs applied, mean total costs, including exenatide costs, were 1,670 higher in the EQW …
RESEARCH DESIGN AND METHODS: Medical resource use data and responses to the EuroQol 5-Dimension (EQ-5D) instrument were collected at …
Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial.
Clarke CE, Patel S, Ives N, Rick CE, Dowling F, Woolley R, Wheatley K, Walker MF, Sackley CM; PD REHAB Collaborative Group. Clarke CE, et al. JAMA Neurol. 2016 Mar;73(3):291-9. doi: 10.1001/jamaneurol.2015.4452. JAMA Neurol. 2016. PMID: 26785394 Clinical Trial.
Secondary outcomes were health-related quality of life (assessed by Parkinson Disease Questionnaire-39 and EuroQol-5D); adverse events; and caregiver quality of life. Outcomes were assessed before trial entry and then 3, 9, and 15 months after randomization. ...Repeated-me …
Secondary outcomes were health-related quality of life (assessed by Parkinson Disease Questionnaire-39 and EuroQol-5D); adverse event …
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
Farmer AJ, Oke J, Stevens R, Holman RR. Farmer AJ, et al. Diabetes Obes Metab. 2011 Dec;13(12):1136-41. doi: 10.1111/j.1463-1326.2011.01475.x. Diabetes Obes Metab. 2011. PMID: 21767341 Clinical Trial.
AIM: No differences in patient health status as measured by the EuroQol-5 Dimension (EQ-5D) questionnaire were observed at 1 year between groups randomized to addition of biphasic, prandial or basal insulin to oral therapy in the treat-to-target in type 2 diabetes trial. . …
AIM: No differences in patient health status as measured by the EuroQol-5 Dimension (EQ-5D) questionnaire were observed at 1 year bet …
15 results